Orthofix has entered into an exclusive license agreement to commercialize Italy-based IGEA's bone, cartilage and soft tissue devices in the U.S. and Canada.
If approved in the U.S., IGEA's products will be marketed under the Orthofix brand.
The IGEA products will strengthen Orthofix's bone growth portfolio, which includes pulsed electromagnetic field products with treatment options such as low-intensity pulsed ultrasound and capacitive coupling for fracture management.
The partnership also includes new technology applications for joint inflammation, pain and cartilage protection.
The combined portfolios will advance Orthofix's "treatment solutions for fracture management and complement our pursuit of new indications for managing soft tissue and joint health such as our ongoing rotator cuff repair IDE clinical study," Jon Serbousek, president and CEO of Orthofix, said in an April 28 news release.